<DOC>
	<DOCNO>NCT02695537</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability Epidiolex various dos 5 mg/kg/day 50 mg/kg/day additional ( add-on ) drug treat debilitating , drug-resistant epilepsy .</brief_summary>
	<brief_title>Safety , Tolerability Epidiolex In Patients ( ( Ages 1 - 19 Years ) With Intractable Epilepsy</brief_title>
	<detailed_description>The specific goal phase I dose find study conduct consecutively enrolled patient 1-18 year age prospectively longitudinally assess safety tolerability , include cognitive effect , CBD various dos 5 mg/kg/day 25 mg/kg/day additional titration subject 50 mg/kg/day . In order participate study , participant need fulfill inclusion exclusion criterion . The goal study fulfill mandate `` Carly 's Law '' provide patient debilitate epileptic condition access CBD add-on treatment . Other care include routine neurological care relate participation CBD study need provide patient ' primary/current treat neurologist .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<criteria>Patients 1 year ( 12 month ) 18 year drug resistant epilepsy confirm video EEG record report Patient history trial lea four drug , include one trial combination two concomitant drug without successful seizure control . Vagal nerve stimulation , RNS deep brain stimulation , ketogenic diet consider equivalent drug trial . Patient suffer epileptic syndrome know refractory treatment , Dravet Lernnox Gastaut Syndrome , may include trial two drug Between 14 baseline antiepileptic drug stable dos minimum 4 week prior submit record review CBD Treatment Approval Committee VNS RBS must stable setting minimum 3 month If ketogenic diet , must stable ration minimum 3 month Review follow patient medical information : Most recent ECG report , Video/EEG monitor report confirm diagnosis epilepsy , Evidence patient fail 4 AEDs indicate , Patient must least 4 clinically countable seizure per month , Seizure history include document history generalize ( drop , atonic , tonic clonic , and/or myoclonic ) seizure , focal seizure without loss consciousness motor component , focal seizure loss consciousness , focal seizure secondary generalization , complex partial seizure motor tonic component , I alter awareness seizure , Results routine test include blood work ( CBC , CMP , LFTs renal panel , Urinary Analysis , level AEDs ) digital copy routine EEG along formal write report perform within 3 month prior submit record CBD Treatment Approval review . If applicable , result metabolic genetic testing perform include submit record review ! If AED dose adjust precede 3 month , level new dose need provide . If applicable , documentation ( include date surgery ) prior VNS , RNS , Corpus Callostomy , epilepsy surgery patient receive . Acceptable method contraception ( abstinence ) woman childbearing potential male patient partner childbearing potential , female patient must have_a negative urine pregnancy test day ofinitating CBD . For patient agree participate optional neuroimaging sub study , MRI screen obtain show patient contraindication receive MRI/fMRI 3 Tesla ( e.g. , metallic artifact ) . Patients able supply investigator seizure calendar past 3 month prior submit record CBD Treatment Approval Committee review . The patient need provide update calendar time enrollment . Approval inclusion CBD Treatment Approval Committee . Current State Alabama Resident Acceptable documentation Alabama residency include follow : state issue ID , driver 's license , patient patient 's parent/ legally authorize representative ( LAR ) . document show patient patient 's parent/LAR rents/owns property state , state voter registration patient patient 's parent/LAR , recent state tax return patient patient 's parent/LAR . Active Psychogenic nonepileptic seizure ( PNES ) ; Patients 1 year freedom PNES exclude , Patients pregnant , breastfeeding , use acceptable method contraception course study three month thereafter , Male patient 's partner child bear potential ; unless willing ensure ( male patient ) partner ( ) use acceptable method contraception course study three month thereafter History substance abuse/addiction , Use medical marijuana CBD base product past 30 day , Initiation offelbamate within last 12 month , Allergy CBD marijuanatype product , ALT &gt; 5 x ULN AST &gt; 5 x ULN , see participant 's laboratory result submit CBD Treatment Approval Committee review . Hemoglobin &lt; 1 0 Hematocrit &lt; 30 WBC &lt; 2000 , see participant 's laboratory result submit CBD Treatment Approval Committee review . In Investigator 's judgement , active medical condition/treatment impact study activity . Unable provide consent ( LAR ) , Unable/Failure comply study visits/requirements and/or instruction . Confirmed diagnosis Dravet Syndrome Lennox Gastaut Syndrome qualifies patient GW Dravet Syndrome LelUlox Gastaut Syndrome randomize controlled clinical trial patient eligible pursuant GW clinical trial enrollment criterion unless ( ) study either actively open enrollment patient UAB expect actively begin enrol patient The University Alabama Birmingham within two ( 2 ) month date patient screen UAB Pediatric CBD Program UAB Adult CBD Program.Primary residence State different Alabama . Subjects contraindication MRI ! fMRI 3 Tesla ( e.g. , metallic artifact ) offer participation optional substudy .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>